Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
- Year invested 2020
- Investment Stage Growth
- Sectors
- Investment Status Current
- Associated Team
- Website geron.com/
- Company Status IPO/Public